R&D For Diseases Of Developing Countries Could Be Driven By Pooled Funds
Executive Summary
WHO committee backs use of pooled funds to finance R&D, nixes priority review vouchers and finds no need for data exclusivity. Novartis’ Paul Herrling, a committee member, notes that governments would be responsible for R&D costs.
You may also be interested in...
FDA Cuts Priority Review Voucher Fee By 32%; J&J In Line For Next Voucher?
By taking into account the incremental costs of priority review and eliminating the IND aspect of the calculation, the agency reduces the fee to redeem a tropical disease priority review voucher to $3.6 million in fiscal year 2013. That may benefit J&J, assuming a pending tuberculosis agent is approved by FDA.
FDA Cuts Priority Review Voucher Fee By 32%; No Takers For FY 2013
By taking into account the incremental costs of priority review and eliminating the IND aspect of the calculation, the agency reduces the fee to redeem a tropical disease priority review voucher to $3.6 million in fiscal year 2013.
Novartis Typhoid Vaccine Seeks Partner After Securing Pakistan Clinical Trial Site
Phase II study is ongoing in Pakistan, a year after Novartis convinced the Pakistani government to lift its ban on clinical trials. Antimalarials with a different mechanism of action than Coartem are in Phase I and II trials.